Hepatitis B virus infection (Q83352950)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19217993%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

title

Hepatitis B virus infection (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19217993%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

1 reference

0 references

1 reference

Yun-Fan Liaw

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19217993%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Chia-Ming Chu

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19217993%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

language of work or name

English

0 references

publication date

1 February 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19217993%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19217993%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

volume

373

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19217993%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

issue

9663

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19217993%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

page(s)

582-592

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19217993%20AND%20SRC:MED&resulttype=core&format=json

Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures

21 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Role of viral factors in the natural course and therapy of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

e antigen and anti-e in the serum of asymptomatic carrier mothers as indicators of positive and negative transmission of hepatitis B virus to their infants

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Hepatitis B virus carrier state in black children in Ovamboland: role of perinatal and horizontal infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Secular trend of age-specific prevalence of hepatitis B surface and e antigenemia in pregnant women in Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Prevalence of HBV precore/core promoter variants in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

HBeAg-negative chronic hepatitis B: from obscurity to prominence

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Should hepatitis B vaccination be introduced into childhood immunisation programmes in northern Europe?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Two decades of universal hepatitis B vaccination in taiwan: impact and implication for future strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Dynamics of hepatitis B virus clearance in chimpanzees

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Viral Clearance Without Destruction of Infected Cells During Acute HBV Infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Role of hepatitis B virus specific cytotoxic T cells in liver damage and viral control

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Immunopathogenesis: role of innate and adaptive immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Chronic infections with hepatotropic viruses: mechanisms of impairment of cellular immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Increased incidence of fulminant hepatic failure in previously unrecognized HBsAg carriers with acute hepatitis independent of etiology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

1 reference

7 January 2021

Unrevealing the natural course of the so-called "inactive HBsAg or HBV carrier state".

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Chronic hepatitis B: current testing strategies.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Pediatric fulminant hepatic failure in endemic areas of hepatitis B infection: 15 years after universal hepatitis B vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Mutations in the basic core promotor and the precore region of hepatitis B virus and their selection in children with fulminant and chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Occult hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Natural history of chronic hepatitis B virus infection in Taiwan: studies of hepatitis B virus DNA in serum

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

1 reference

7 January 2021

Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Subcellular localization of hepatitis B core antigen in relation to hepatocyte regeneration in chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Precore stop mutant in HBeAg-positive patients with chronic hepatitis B: clinical characteristics and correlation with the course of HBeAg-to-anti-HBe seroconversion

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Relationship between the development of precore and core promoter mutations and hepatitis B e antigen seroconversion in patients with chronic hepatitis B virus.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Prognostic factors in severe exacerbation of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Clinical relevance of hepatitis B virus genotype in children with chronic infection and hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Epidemiological study of hepatitis B virus genotypes, core promoter and precore mutations of chronic hepatitis B infection in Hong Kong.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Natural history of chronic HBV infection: a cohort study with up to 12 years follow-up in North Greece (part of the Interreg I-II/EC-project).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Viremia profiles in children with chronic hepatitis B virus infection and spontaneous e antigen seroconversion

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Chronic hepatitis B e antigen (HBeAg) negative, anti-HBe positive hepatitis B: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Spontaneous relapse of hepatitis in inactive HBsAg carriers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Hepatitis B virus DNA prediction rules for hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Risk and predictors of mortality associated with chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

The development of cirrhosis in patients with chronic type B hepatitis: A prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Hepatitis B e antigen and the risk of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Significance of hepatitis B genotype in acute exacerbation, HBeAg seroconversion, cirrhosis-related complications, and hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Comparison of genotypes C and D of the hepatitis B virus in Japan: a clinical and molecular biological study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Long-term outcome of chronic hepatitis B based on histological grade and stage.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Hepatitis B virus-related cirrhosis: natural history and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Temporal relationship between hepatitis B virus enhancer II/basal core promoter sequence variation and risk of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

The clinical significance of persistently normal ALT in chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Interferon-alpha for HBeAg-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Telbivudine versus lamivudine in patients with chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Lamivudine for patients with chronic hepatitis B and advanced liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Histological outcome during long-term lamivudine therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Hepatitis B: reflections on the current approach to antiviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Successful Treatment with Peginterferon alfa-2b of HBeAg-positive HBV Non-Responders to Standard Interferon or Lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Chronic hepatitis B: a global health problem requiring coherent worldwide treatment strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Management of hepatitis B: summary of a clinical research workshop

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

Hepatitis B reactivation after chemotherapy: two decades of clinical research

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960207-5

7 January 2021

10.1016/S0140-6736(09)60207-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19217993%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

1 reference